Status:

COMPLETED

OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)

Lead Sponsor:

Versailles Hospital

Collaborating Sponsors:

Maisonneuve-Rosemont Hospital

University Hospital, Bordeaux

Conditions:

Chronic Myelogenous Leukemia, BCR/ABL Positive

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This protocol is a multicentric interventional phase II study from the French CML Intergroup (FILMC). The core of the protocol is to explore the efficacy and safety of an optimization strategy consis...

Eligibility Criteria

Inclusion

  • Male or female patient ≥ 18 years
  • ECOG Performance Status score 0-2
  • Philadelphia chromosome positive newly diagnosed (≤ 3 months) CP-CML
  • patients not previously treated except with hydroxyurea or imatinib (less than 4 weeks for imatinib)
  • Signed written inform consent
  • Adequate hepatic function defined as: total bilirubin ≤ 2.0 times the institutional ULN; ALT and AST ≤ 2.5 times the institutional upper limit of normal (ULN).
  • Adequate renal function defined as serum creatinine ≤ 3 times the institutional ULN.
  • Women of childbearing potential (WOCBP) must be using an adequate method of contraception.

Exclusion

  • Patients with BCR-ABL positive, Philadelphia negative CML
  • Patient previously treated with a tyrosine kinase inhibitor (TKI) except with imatinib during less than 4 weeks.
  • Pregnancy
  • Active malignancy
  • Uncontrolled or significant cardiovascular disease
  • Patients with QTc \> 450 ms
  • Significant bleeding disorder unrelated to CML
  • Concurrent severe diseases which exclude the administration of therapy

Key Trial Info

Start Date :

May 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2013

Estimated Enrollment :

289 Patients enrolled

Trial Details

Trial ID

NCT01916785

Start Date

May 1 2009

End Date

December 1 2013

Last Update

August 22 2016

Active Locations (34)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 9 (34 locations)

1

Southern Alberta Cancer Research Institute

Calgary, Canada

2

Hôpital Charles LeMoyne

Greenfield Park, Canada

3

Queen elisabeth II Health Sciences Center

Halifax, Canada

4

CH Pierre LeGardeur

Lachenaie, Canada